{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:02:11Z","timestamp":1786489331566,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65467-8","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:58:59Z","timestamp":1764079139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE\/PKUPH-sarcoma 11): a randomized phase II study"],"prefix":"10.1038","volume":"16","author":[{"given":"Lu","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuisheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunkun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7277-0958","authenticated-orcid":false,"given":"Yingqi","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3993-974X","authenticated-orcid":false,"given":"Haiyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6876-7361","authenticated-orcid":false,"given":"Tao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9097-3249","authenticated-orcid":false,"given":"Xiaodong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"65467_CR1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdr151","volume":"23","author":"G Grignani","year":"2012","unstructured":"Grignani, G. et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann. Oncol. 23, 508\u2013516 (2012).","journal-title":"Ann. Oncol."},{"key":"65467_CR2","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1200\/JCO.18.02374","volume":"37","author":"LE Davis","year":"2019","unstructured":"Davis, L. E. et al. Randomised double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J. Clin. Oncol. 37, 1424\u20131431 (2019).","journal-title":"J. Clin. Oncol."},{"key":"65467_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","volume":"20","author":"F Duffaud","year":"2019","unstructured":"Duffaud, F. et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 20, 120\u2013133 (2019).","journal-title":"Lancet Oncol."},{"key":"65467_CR4","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1634\/theoncologist.2018-0542","volume":"24","author":"L Xie","year":"2019","unstructured":"Xie, L. et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist 24, e542\u2013e550 (2019).","journal-title":"Oncologist"},{"key":"65467_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100250","volume":"6","author":"N Gaspar","year":"2021","unstructured":"Gaspar, N. et al. Phase I\/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050). ESMO Open 6, 100250 (2021).","journal-title":"ESMO Open"},{"key":"65467_CR6","doi-asserted-by":"crossref","unstructured":"Xie L. et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer. 8, e000798 (2020).","DOI":"10.1136\/jitc-2020-000798"},{"key":"65467_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-43085-6_1","volume":"1258","author":"C Schott","year":"2020","unstructured":"Schott, C., Shah, A. T. & Sweet-Cordero, E. A. Genomic complexity of osteosarcoma and its implication for preclinical and clinical targeted therapies. Adv. Exp. Med Biol. 1258, 1\u201319 (2020).","journal-title":"Adv. Exp. Med Biol."},{"key":"65467_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-018-0903-9","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott, L. J. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs 78, 747\u2013758 (2018).","journal-title":"Drugs"},{"key":"65467_CR9","first-page":"14","volume":"19","author":"G Blackledge","year":"1992","unstructured":"Blackledge, G. et al. Experience with ifosfamide in the EORTC soft tissue and bone sarcoma group. Semin Oncol. 19, 14\u201318 (1992).","journal-title":"Semin Oncol."},{"key":"65467_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0959-8049(96)00439-X","volume":"33","author":"JC Gentet","year":"1997","unstructured":"Gentet, J. C. et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur. J. Cancer 33, 232\u2013237 (1997).","journal-title":"Eur. J. Cancer"},{"key":"65467_CR11","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.2217\/fon-2021-0743","volume":"17","author":"N Gaspar","year":"2021","unstructured":"Gaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E. & Bautista, F. OLIE, ITCC-082: a phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed\/refractory osteosarcoma. Future Oncol. 17, 4249\u20134261 (2021).","journal-title":"Future Oncol."},{"key":"65467_CR12","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S1470-2045(21)00387-9","volume":"22","author":"N Gaspar","year":"2021","unstructured":"Gaspar, N. et al. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1\/2 study. Lancet Oncol. 22, 1312\u20131321 (2021).","journal-title":"Lancet Oncol."},{"key":"65467_CR13","unstructured":"Gaspar, N. et al. Lenvatinib plus ifosfamide and etoposide in children and young adults with relapsed osteosarcoma: a phase 2 randomized clinical trial. JAMA Oncol. 10, 1645\u20131653 (2024)."},{"key":"65467_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3892\/ol.2021.12813","volume":"22","author":"L Xie","year":"2021","unstructured":"Xie, L. et al. Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: a retrospective study in two centres. Oncol. Lett. 22, 552 (2021).","journal-title":"Oncol. Lett."},{"key":"65467_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.696865","volume":"11","author":"L Xie","year":"2021","unstructured":"Xie, L. et al. Management of apatinib-related adverse events in patients with advanced osteosarcoma from four prospective trials: Chinese sarcoma study group experience. Front. Oncol. 11, 696865 (2021).","journal-title":"Front. Oncol."},{"key":"65467_CR16","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2015.65.5381","volume":"34","author":"JP Lagmay","year":"2016","unstructured":"Lagmay, J. P. et al. Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children\u2019s Cancer Group, Pediatric Oncology Group, and Children\u2019s Oncology Group: learning from the past to move forward. J. Clin. Oncol. 34, 3031\u20133038 (2016).","journal-title":"J. Clin. Oncol."},{"key":"65467_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102625","volume":"120","author":"R van Ewijk","year":"2023","unstructured":"van Ewijk, R. et al. A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?. Cancer Treat. Rev. 120, 102625 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"65467_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41416-021-01448-0","volume":"125","author":"B Schulte","year":"2021","unstructured":"Schulte, B. et al. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Br. J. Cancer 125, 528\u2013533 (2021).","journal-title":"Br. J. Cancer"},{"key":"65467_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"65467_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85, 365\u2013376 (1993).","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65467-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:59:01Z","timestamp":1764079141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65467-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65467"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65467-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5641573\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.W., S.S., Z.C. and Z.P. are employees of Jiangsu Hengrui Pharmaceuticals. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10473"}}